The Shuttle interacts strongly with the membrane to initiate the permeabilization process.
While the Shuttle remains in the membrane, the free therapeutic compound translocates to the cytoplasm.
The Feldan Shuttle provides a unique way to deliver therapeutic compounds inside cells and is allowing the development of next-generation therapies.
The Feldan Shuttle allows untapped and highly specific therapeutics compounds to access intracellular pathways that can be targeted for therapeutic interventions. The versatility of the technology translates into multiple strategies to correct diseases:
Having access to the intracellular space allows the targeting and correction of dysregulated proteins and signalling pathways associated with diseases.
The Feldan Shuttle allows the development of a new generation of therapies for diseases caused by the absence of intracellular proteins.
The Feldan Shuttle allows the delivery of gene-editing nucleases in their active protein form. This allows precise and safe correction of impaired genes.
Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr., Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y. PMID: 31659165
Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431